Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion
暂无分享,去创建一个
N. Clumeck | S. De Wit | P. Hermans | V. van de Velde | E. O'Doherty | B. Sommereijns | G. Cauwenbergh | R. Westenborghs
[1] D. Richman,et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[2] E A Emini,et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.
[3] H. Mitsuya,et al. Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. , 1991, Blood.
[4] M. Youle,et al. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex , 1991, The Lancet.
[5] Erik De Clercq,et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.